{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:58:41Z","timestamp":1790348321686,"version":"4.1.0"},"reference-count":64,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"unspecified","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Diab Res Care"],"accepted":{"date-parts":[[2026,9,12]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>The progressive decline in functional \u03b2-cell mass represents a fundamental, unmet challenge in type 2 diabetes (T2DM) management. Dorzagliatin (HMS5552), a fourth-generation, dual-acting, and glucose-dependent glucokinase activator (GKA), offers a distinct mechanistic approach that aims to move beyond symptomatic glycemic control toward potential glucose sensor modulation. This review critically synthesizes the development of dorzagliatin, designed to overcome the hypoglycemia and tachyphylaxis of earlier GKAs. While its unique allosteric mechanism enables synchronized restoration of insulin secretion and hepatic glucose metabolism, we critically evaluate its clinical positioning. Observational data from the DREAM study suggest sustained drug-free glycemic maintenance; however, we emphasize that these findings do not yet meet the rigorous 2021 American Diabetes Association\/European Association for the Study of Diabetes consensus definition of \u201cdiabetes remission\u201d and require validation through randomized withdrawal trials. Furthermore, we address the critical absence of long-term cardiovascular outcomes trials (CVOTs) and the theoretical concerns regarding hepatic de novo lipogenesis. We also propose a synergistic framework for combining dorzagliatin with sodium-glucose cotransporter-2 inhibitors to counteract compensatory endogenous glucose production, positioning it as a precision-driven component in the evolving T2DM therapeutic landscape. Should future CVOTs demonstrate safety and efficacy, GKAs like dorzagliatin could potentially be integrated into treatment guidelines, possibly as a \u201csensor-calibrator\u201d for a subset of patients identified through metabolic and genetic phenotyping. However, it must be emphasized that no CVOT data are currently available for dorzagliatin.<\/jats:p>","DOI":"10.1136\/bmjdrc-2026-006217","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:00:20Z","timestamp":1790344820000},"page":"e006217","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Resetting the glucose sensor: dorzagliatin and the evolution of glucokinase activation in diabetes therapy"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6068-1299","authenticated-orcid":false,"given":"Mingxing","family":"Chang","sequence":"first","affiliation":[{"name":"The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peipu","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Health Management Center, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guifang","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Health Management Center, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"2026092507001280000_14.5.e006217.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119"},{"key":"2026092507001280000_14.5.e006217.2","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s00125-025-06600-6","article-title":"Bridging the variant-to-function gap in type 2 diabetes: advances and challenges","volume":"69","author":"Maynard","year":"2026","journal-title":"Diabetologia"},{"key":"2026092507001280000_14.5.e006217.3","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S009"},{"key":"2026092507001280000_14.5.e006217.4","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1007\/s00125-025-06439-x","article-title":"Treatment discontinuation among users of GLP-1 receptor agonists and SGLT2 inhibitors in a national population of individuals with type 2 diabetes","volume":"68","author":"Lim","year":"2025","journal-title":"Diabetologia"},{"key":"2026092507001280000_14.5.e006217.5","doi-asserted-by":"crossref","DOI":"10.14309\/01.ajg.0001130404.86228.5e","article-title":"S736 Gastrointestinal Tolerability of Tirzepatide Compared With GLP-1 Receptor Agonists, Insulin and Placebo in Obesity: A Meta-Analysis of 11,000+ Subjects","volume":"120","author":"Shah","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"2026092507001280000_14.5.e006217.6","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-083039","article-title":"Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis","volume":"390","author":"Nong","year":"2025","journal-title":"BMJ"},{"key":"2026092507001280000_14.5.e006217.7","doi-asserted-by":"crossref","first-page":"e4975","DOI":"10.1210\/clinem\/dgaa666","article-title":"Let\u2019s Be More Sensitive\u2014How SGLT-2 Inhibitors and GLP-1 Receptor Agonists Affect \u03b2-Cell Function in Type 2 Diabetes: Comment on \u201cImproved Beta Cell Glucose Sensitivity Plays Predominant Role in the Decrease in HbA1c with Cana and Lira in T2DM\u201d by Ali et al","volume":"105","author":"Pratley","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2026092507001280000_14.5.e006217.8","doi-asserted-by":"publisher","DOI":"10.1038\/361362a0"},{"key":"2026092507001280000_14.5.e006217.9","doi-asserted-by":"crossref","DOI":"10.1111\/1753-0407.13544","article-title":"Clinical investigation of glucokinase activators for the restoration of glucose homeostasis in diabetes","volume":"16","author":"Li","year":"2024","journal-title":"J Diabetes"},{"key":"2026092507001280000_14.5.e006217.10","first-page":"E1","article-title":"New perspectives on pancreatic islet glucokinase","volume":"246","author":"Meglasson","year":"1984","journal-title":"Am J Physiol"},{"key":"2026092507001280000_14.5.e006217.11","doi-asserted-by":"publisher","DOI":"10.2337\/diab.35.10.1163"},{"key":"2026092507001280000_14.5.e006217.12","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.1987.67.4.1185"},{"key":"2026092507001280000_14.5.e006217.13","doi-asserted-by":"publisher","DOI":"10.2337\/diab.39.6.647"},{"key":"2026092507001280000_14.5.e006217.14","doi-asserted-by":"publisher","DOI":"10.1126\/science.1084073"},{"key":"2026092507001280000_14.5.e006217.15","doi-asserted-by":"crossref","DOI":"10.3390\/metabo16040264","article-title":"Evidence That Oscillations in Glucose Metabolism Promote Optimal Islet Function","volume":"16","author":"List","year":"2026","journal-title":"Metabolites"},{"key":"2026092507001280000_14.5.e006217.16","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-008-8322-9"},{"key":"2026092507001280000_14.5.e006217.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2024.12.007"},{"key":"2026092507001280000_14.5.e006217.18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.29090\/psa.2020.01.019.0005","article-title":"Efficacy and safety of glucokinase activators for type 2 diabetes mellitus: A systematic review","volume":"47","author":"Dian Marani Kurnianta","year":"2020","journal-title":"Pharm Sci Asia"},{"key":"2026092507001280000_14.5.e006217.19","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.2337\/db25-0066","article-title":"Functional and Mechanistic Explanation for the Unique Clinical Success of the Glucokinase Activator Dorzagliatin in the Treatment of Type 2 Diabetes","volume":"74","author":"Roman","year":"2025","journal-title":"Diabetes"},{"key":"2026092507001280000_14.5.e006217.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2012.02184.x"},{"key":"2026092507001280000_14.5.e006217.21","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-nutr-071715-051145"},{"key":"2026092507001280000_14.5.e006217.22","doi-asserted-by":"crossref","DOI":"10.1111\/1753-0407.13563","article-title":"Recent drug development of dorzagliatin, a new glucokinase activator, with the potential to treat Type 2 diabetes: A review study","volume":"16","author":"Jiang","year":"2024","journal-title":"J Diabetes"},{"key":"2026092507001280000_14.5.e006217.23","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20110440"},{"key":"2026092507001280000_14.5.e006217.24","doi-asserted-by":"publisher","DOI":"10.1042\/BST0330306"},{"key":"2026092507001280000_14.5.e006217.25","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.2337\/db24-1130","article-title":"Effects of Dorzagliatin, a Glucokinase Activator, on \u03b1- and \u03b2-Cell Function in Individuals With Impaired and Normal Glucose Tolerance","volume":"74","author":"Bai","year":"2025","journal-title":"Diabetes"},{"key":"2026092507001280000_14.5.e006217.26","doi-asserted-by":"crossref","first-page":"30105","DOI":"10.1016\/S2213-8587(18)30105-0","article-title":"Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study","volume":"6","author":"Zhu","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026092507001280000_14.5.e006217.27","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/dom.15370","article-title":"Improvement of early-phase insulin secretion is an independent factor for achieving glycaemic control: A pooled analysis of SEED and DAWN study","volume":"26","author":"Feng","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2026092507001280000_14.5.e006217.28","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2337\/db21-117-LB","article-title":"117-LB: Glucokinase Activator Dorzagliatin (HMS5552) Regulates GLP-1 Release in T2D Patients and Is Synergistic with Sitagliptin and Empagliflozin in Optimizing Beta-Cell Function","volume":"70","author":"Chen","year":"2021","journal-title":"Diabetes"},{"key":"2026092507001280000_14.5.e006217.29","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01803-5"},{"key":"2026092507001280000_14.5.e006217.30","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00034.2016"},{"key":"2026092507001280000_14.5.e006217.31","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1111\/dom.13359","article-title":"Hypothalamic arcuate nucleus glucokinase regulates insulin secretion and glucose homeostasis","volume":"20","author":"Ma","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2026092507001280000_14.5.e006217.32","doi-asserted-by":"publisher","DOI":"10.1002\/cne.25312"},{"key":"2026092507001280000_14.5.e006217.33","doi-asserted-by":"crossref","first-page":"1755359","DOI":"10.3389\/fendo.2025.1755359","article-title":"Dorzagliatin shows potential in preventing cognitive impairment in diabetes: evidence from Mendelian randomization analysis and animal study","volume":"16","author":"Ni","year":"2026","journal-title":"Front Endocrinol"},{"key":"2026092507001280000_14.5.e006217.34","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1496"},{"key":"2026092507001280000_14.5.e006217.35","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2024-004291","article-title":"Glucokinase activators and imeglimin: new weaponry in the armamentarium against type 2 diabetes","volume":"12","author":"Sj\u00f6holm","year":"2024","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2026092507001280000_14.5.e006217.36","first-page":"1619","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study","volume":"10","author":"Xu","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"2026092507001280000_14.5.e006217.37","unstructured":"Zhu DL , Ding YH , Xiao DW , et al . Clinically differentiated glucokinase activator hms5552: effective control of 24--hour glucose and improvement of \u03b2--cell function in t2dm patients. ADA 75th Scientific Session; Boston, 2015"},{"key":"2026092507001280000_14.5.e006217.38","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1111\/dom.13338","article-title":"Dorzagliatin (HMS5552), a novel dual\u2010acting glucokinase activator, improves glycaemic control and pancreatic \u03b2\u2010cell function in patients with type 2 diabetes: A 28\u2010day treatment study using biomarker\u2010guided patient selection","volume":"20","author":"Zhu","year":"2018","journal-title":"Diabetes Obesity Metabolism"},{"key":"2026092507001280000_14.5.e006217.39","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01802-6"},{"key":"2026092507001280000_14.5.e006217.40","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1111\/dom.15179","article-title":"Diabetes remission in drug-na\u00efve patients with type 2 diabetes after dorzagliatin treatment: A prospective cohort study","volume":"25","author":"Zeng","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2026092507001280000_14.5.e006217.41","doi-asserted-by":"publisher","DOI":"10.2337\/dci21-0034"},{"key":"2026092507001280000_14.5.e006217.42","doi-asserted-by":"publisher","DOI":"10.2337\/db13-0052"},{"key":"2026092507001280000_14.5.e006217.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2022.12.007"},{"key":"2026092507001280000_14.5.e006217.44","doi-asserted-by":"crossref","unstructured":"Zeng J , Gan S , Dong X , et al . 115-LB: Dorzagliatin Showed Sustained Remission in an Observational Study after Discontinuation of Treatment in T2D Patients Who Achieved Good Glycemic Control with Dorzagliatin Monotherapy. Diabetes 2022;71. doi:10.2337\/db22-115-LB","DOI":"10.2337\/db22-115-LB"},{"key":"2026092507001280000_14.5.e006217.45","doi-asserted-by":"crossref","unstructured":"Feng L , Guo Q , Chen C , et al . 117-LB: Glucokinase Activator Restores Glucose Sensitivity and Early-Phase Insulin Secretion in T2DM Patient\u2014A Post Hoc Analysis of Dorzagliatin. Diabetes 2022;71. doi:10.2337\/db22-117-LB","DOI":"10.2337\/db22-117-LB"},{"key":"2026092507001280000_14.5.e006217.46","doi-asserted-by":"publisher","DOI":"10.2337\/db22-0708"},{"key":"2026092507001280000_14.5.e006217.47","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s40261-024-01351-5","article-title":"Should Glucokinase be Given a Chance in Diabetes Therapeutics? A Clinical-Pharmacological Review of Dorzagliatin and Lessons Learned So Far","volume":"44","author":"Kaur","year":"2024","journal-title":"Clin Drug Investig"},{"key":"2026092507001280000_14.5.e006217.48","doi-asserted-by":"crossref","unstructured":"Dardano A , Bianchi C , Garofolo M , et al . The current landscape for diabetes treatment: Preventing diabetes-associated CV risk. Atherosclerosis 2024;394. doi:10.1016\/j.atherosclerosis.2024.117560","DOI":"10.1016\/j.atherosclerosis.2024.117560"},{"key":"2026092507001280000_14.5.e006217.49","doi-asserted-by":"crossref","first-page":"112246","DOI":"10.1016\/j.diabres.2025.112246","article-title":"Genetically proxied glucokinase activation and risk of diabetic complications: Insights from phenome-wide and multi-omics mendelian randomization","volume":"225","author":"Zhang","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"key":"2026092507001280000_14.5.e006217.50","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12933-024-02321-z","article-title":"Impaired GK-GKRP interaction rather than direct GK activation worsens lipid profiles and contributes to long-term complications: a Mendelian randomization study","volume":"23","author":"Wang","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"2026092507001280000_14.5.e006217.51","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25010571","article-title":"New-Generation Glucokinase Activators: Potential Game-Changers in Type 2 Diabetes Treatment","volume":"25","author":"Haddad","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026092507001280000_14.5.e006217.52","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40265-020-01278-z","article-title":"Glucokinase Activators for Type 2 Diabetes: Challenges and Future Developments","volume":"80","author":"Toulis","year":"2020","journal-title":"Drugs"},{"key":"2026092507001280000_14.5.e006217.53","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41574-020-0355-7","article-title":"Pancreatic \u03b2-cells in type 1 and type 2 diabetes mellitus: different pathways to failure","volume":"16","author":"Eizirik","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"2026092507001280000_14.5.e006217.54","doi-asserted-by":"publisher","DOI":"10.2337\/dc26-S006"},{"key":"2026092507001280000_14.5.e006217.55","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-2684"},{"key":"2026092507001280000_14.5.e006217.56","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/dom.14697","article-title":"Impact of the hepatoselective glucokinase activator TTP399 on ketoacidosis during insulin withdrawal in people with type 1 diabetes","volume":"24","author":"Klein","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"2026092507001280000_14.5.e006217.57","article-title":"Dorzagliatin: A Breakthrough Glucokinase Activator Coming on Board to Treat Diabetes Mellitus","volume":"16","author":"Raju","year":"2024","journal-title":"Cureus"},{"key":"2026092507001280000_14.5.e006217.58","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.2337\/dc23-2417","article-title":"Hypoglycemic Response to Dorzagliatin in a Patient With GCK-MODY","volume":"47","author":"Zhao","year":"2024","journal-title":"Diabetes Care"},{"key":"2026092507001280000_14.5.e006217.59","doi-asserted-by":"crossref","first-page":"329","DOI":"10.4330\/wjc.v14.i6.329","article-title":"Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes","volume":"14","author":"Singh","year":"2022","journal-title":"World J Cardiol"},{"key":"2026092507001280000_14.5.e006217.60","doi-asserted-by":"publisher","DOI":"10.2337\/dci19-0028"},{"key":"2026092507001280000_14.5.e006217.61","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.2337\/db24-1036","article-title":"Genotype-Phenotype Discrepancies in Family Members With a Novel Glucokinase Mutation: Insights Into GCK-MODY and Its Interplay With Insulin Resistance","volume":"74","author":"Ji","year":"2025","journal-title":"Diabetes"},{"key":"2026092507001280000_14.5.e006217.62","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00125-021-05390-x","article-title":"Biphasic dynamics of beta cell mass in a mouse model of congenital hyperinsulinism: implications for type 2 diabetes","volume":"64","author":"Tornovsky-Babeay","year":"2021","journal-title":"Diabetologia"},{"key":"2026092507001280000_14.5.e006217.63","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202504049R","article-title":"Contrasting Effects of Chronic Glucokinase Activation and Inhibition on Pancreatic Beta-Cell Function","volume":"40","author":"Lloyd","year":"2026","journal-title":"FASEB J"},{"key":"2026092507001280000_14.5.e006217.64","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/s42255-024-01049-0","article-title":"Weak neuronal glycolysis sustains cognition and organismal fitness","volume":"6","author":"Jimenez-Blasco","year":"2024","journal-title":"Nat Metab"}],"container-title":["BMJ Open Diabetes Research &amp; Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjdrc-2026-006217","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:00:27Z","timestamp":1790344827000},"score":1,"resource":{"primary":{"URL":"https:\/\/drc.bmj.com\/lookup\/doi\/10.1136\/bmjdrc-2026-006217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":64,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9,25]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/bmjdrc-2026-006217"],"URL":"https:\/\/doi.org\/10.1136\/bmjdrc-2026-006217","relation":{},"ISSN":["2052-4897"],"issn-type":[{"value":"2052-4897","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}